Research Activity,"Project Title 
(and link to additional information, if available)",Topic,Agency and Office Name,Country(ies) in which research is/will be conducted,Status,Upcoming Milestones,Anticipated Completion,Brief Description,Project Link
Vaccine Immunogenicity Study,A Multicenter Trial Evaluating Alterative Dosing Strategies of the JYNNEOS MVA-BN mpox Vaccine,Vaccine,NIH/NIAID,Domestic,Active enrolling (started 9/9/2022),2023 Q1: Initial immunogenicity analysis (peak response),2023 Q2,"This study is a Phase 2 randomized, open-label, non-placebo controlled, multi-site clinical trial that will evaluate two intradermal (ID) regimens for MVA-BN vaccine compared to the standard subcutaneous (SC) regimen in healthy, vaccinia-naïve adults 18 to 50 years of age, inclusive. This study will provide more information on the immunogenicity and reactogenicity of intradermal dosing and may enable the US and the world to further stretch supplies of Jynneos vaccine to address the current and future MPX outbreak, as well as a potential smallpox attack.",https://clinicaltrials.gov/ct2/show/NCT05512949?cond=Monkeypox&fund=01&draw=2
Vaccine Immunogenicity Study (Vaccine),A Multicenter Trial Evaluating Alterative Dosing Strategies of the JYNNEOS MVA-BN mpox Vaccine,Vaccine,NIH/NIAID,Domestic,Stage 2 of the above listed study.,2023 Q1 Enrollment to begin,2025,"This study is a Phase 2 randomized, open-label, non-placebo controlled, multi-site clinical trial that will evaluate the standard subcutaneous (SC) regimen in vaccina naïve healthy adolescents ages 12-17 and  vaccinia-naïve adults 18 to 50 years of age, inclusive. This study will provide more information on the immunogenicity and reactogenicity in the adolescent population.",https://clinicaltrials.gov/ct2/show/NCT05512949?cond=Monkeypox&fund=01&draw=2
Drug-Vaccine Interaction Study,Study to evaluate the immunogenicity profile and potential immunological interference of JYNNEOS while concomitantly administering TPOXX for 28 days,Vaccine,DoD/JPM CBRN Medical,USA,Ongoing,FY2023 Q3: Completion of Database Lock,2023-10-31T00:00:00.000,"This study is a Phase 2, randomized, open-label (JYNNEOS), double-blind (TPOXX and placebo), placebo-controlled, multicenter drug vaccine interaction study to examine whether administering TPOXX with JYNNEOS concomitantly affects JYNNEOS immunogenicity in healthy adult subjects. A total of 100 subjects (50 per treatment group), ages 18 to 42, inclusive, will be enrolled and randomly assigned to 1 of 2 treatment groups. Understanding that both JYNNEOS and TPOXX can be administered safely in healthy adult subjects will help support the CDC EAP for orthopoxvirus treatment.",https://clinicaltrials.gov/ct2/show/NCT04957485
Vaccine Effectiveness Study,National estimates of post-licensure vaccine performance and effectiveness,Vaccine,CDC,Domestic,Planned,"2022 Q3: begin project data collection

2023 Q1: complete data collection and analysis",2023 Q2: multi-jurisdictional case-control study,"CDC will: 1) Collect data from states and local jurisdictions on the vaccination status of diagnosed mpox cases to determine real-world vaccine performance.  Incidence of these post-vaccination cases will be calculated and used to prospectively update trends. This analysis will be a rapid evaluation of whether the vaccine has been successful in preventing infection and/or attenuating the course of illness. 2) Conduct a multi-jurisdictional case control study to produce vaccine effectiveness estimates on several strata, including dose, route of administration, and other factors. 3) Assist other jurisdictions on their own case---control studies, including those planned in California, NYC, and the Veteran’s Administration.

These efforts will contribute to a robust understanding of the contribution of vaccination to halting transmission and will provide insights into the long-term efficacy of novel, dose-sparing routes of administration.",
Vaccine Effectiveness Case Series Evaluation,Post-vaccination case series,Vaccine,CDC,Domestic,Planned,2022 Q3: project will begin data collection,Completed 2022 Q4,"This is a post-vaccination case series to collect additional data points from post-vaccination cases and assess factors associated with becoming infected with mpox following vaccination. This study will provide timely information about the effectiveness of vaccination to decrease the spread of virus within the population most affected and will highlight circumstances associated with breakthrough infections. Project completed and published Dec 30, 2022",http://dx.doi.org/10.15585/mmwr.mm715152a2
Vaccine Utilization Study,Evaluating vaccine administration data,Vaccine,CDC,Domestic,Ongoing; data analyzed weekly,2022 Q3: project will begin data collection,Ongoing throughout vaccination,Vaccine administration data is being collected from states and selected local jurisdictions and territories via CDC’s Immunization Data Lake (IZDL)system and analyzed and updated weekly. This study will provide insights into the equitable distribution and population coverage of vaccines that have been distributed by the federal government to protect individuals from infection and prevent ongoing virus transmission. High level data on mpox vaccine coverage (one and two doses) among at-risk population were shared with each jurisdiction and with CDC and WH leadership in December 2022; discussion ongoing regarding goals/expectations of optimal coverage among at-risk population.,
Vaccine Safety Surveillance,Monitoring safety and adverse events,Vaccine,CDC,Domestic,Ongoing (VAERS and VSD),2022 Q4: v-safe will begin data collection,Ongoing throughout vaccination,"Efforts include spontaneous reporting to Vaccine Adverse Event Reporting System (VAERS); healthcare-based surveillance in Vaccine Safety Datalink (VSD); and voluntary surveys using v-safe. This study will provide vital information to ensure that there are no unintended harms from the vaccines administered during this outbreak, which are intended to protect individuals from infection and prevent ongoing virus transmission.",https://vaers.hhs.gov/
Vaccine Immunogenicity Study,Evaluating immune response to JYNNEOS vaccine,Vaccine,CDC,Domestic,Ongoing; Laboratory work is ongoing. Enrollment for 6-7 month timepoint has begun,"2023 Q1-Q2:
Publish results",2023 Q2,"Conducted in collaboration with DC Health, CDC is evaluating the immune response to JYNNEOS vaccine among persons at elevated risk of MPX exposure. Serologic immune response is being assessed at days 0, 28, and 42–56 after single dose of JYNNEOS vaccination. Participants are also being enrolled for a 6-7 month timepoint, to determine the longevity of antibody response, with additional 1, 1.5 and 2 year time points are also planned in future. This study will provide vital information to ensure that the vaccines administered during this outbreak are effective (immunogenic) and generate a uniform, rapid immunologic response among people of different ages and background health status. The study samples from first 3 time points are partially completed. Neutralization titers determination is in progress, and the study is being drafted for publication.",
Novel Vaccine Evaluation,Pre-clinical Evaluation of a psoralen-inactivated monkeypox vaccine in mice,Vaccine,NMRC,Domestic,Ongoing,Expect initial results in Fall 2023,2024,Monkeypox viral stocks grown and evaluated in preclinical testing using the psoralen-inactivation vaccine development platform,
Next Generation Vaccine Research,Development of mRNA-based mpox vaccines,Vaccine,NIH/NIAID,Domestic,Ongoing,"Preprint reporting initial results:

A mpox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives protection against lethal orthopoxviral challenge",Ongoing,NIAID’s Division of Intramural Research (DIR) and Vaccine Research Center (VRC) are developing mRNA-based mpox vaccines in collaboration with Moderna and conducting efficacy studies in animal models to select lead vaccine candidates. These studies will advance potential alternative mpox vaccines.,https://www.biorxiv.org/content/10.1101/2022.12.17.520886v1
Next Generation Vaccine Research,Next Generation Vaccine Research,Vaccine,NIH/NIAID,Domestic,Ongoing,2022 Q4 Study initiated,2023 Q4,This study includes testing a portfolio of well-characterized novel adjuvants that induce different types of immune responses (Th1/Th2/Th17) to identify the optimal formulations for subunit and mRNA-based mpox vaccines.,
Vaccine efficacy,Assessment of antibody response to mpox vaccine,Vaccine,CDC,Domestic International: DRC,Ongoing,2022 Q4,Duration is 5 years,"In the DRC study, CDC is expanding an ongoing vaccine study to evaluate (a) the persistence of antibodies in study participants who received the booster vaccination (b) administration and evaluation of an intradermal booster vaccination with JYNNEOS in individuals who had previously received the 2 dose series and (c) the occurrence of MPX disease in vaccinated and boosted study participants to inform effectiveness assessments.  

This study will utilize an existing cohort of individuals at high-risk of MPXV infection (healthcare workers) that reside and work in an area where there is enhanced surveillance for human infections with MPXV.    In the USA study, this is a new study to conduct longitudinal surveillance for vaccine effectiveness and immunologic reactogenicity among sexual health clinic patients in Los Angeles in collaboration with UCLA and various partners. The immunogenicity and durability of standard and alternative vaccination regimens remain unknown; furthermore, no prior studies have determined the clinical effectiveness of MPXV vaccination for prevention of MPXV infection and disease within the populations affected by the current outbreak, which is driven primarily by sexual transmission.",
Real World Vaccine Efficacy Study Using VA Data,"Effectiveness of Dryvaxx®, ACAM2000 and JYNNEOS for Preventing Mpox among the VA Population",Vaccine,"VA/VHA, AFHSD/ DHA",Domestic,Initiated,Preparing report; submitting manuscript for publication in a peer-reviewed journal,2023 Q1,"This is an analysis of VA and DoD data to explore the effectiveness of smallpox vaccination for mpox illness prevention on Veterans in VA healthcare. Major experimental aims are toto identify how much immunity wanes: 1) with time since vaccination, and 2) with age, using a test negative case control design. This study will provide a large real-world evaluation and evidence that will define the use of these vaccines in the broader public health strategy for containing the global mpox outbreak. A manuscript was submitted and reviewed at a leading medical journal; reviewers’ questions were answered; journal requested ‘revise and resubmit’ as a letter to the editor. which is in process. Presented results at the Conference on Retroviruses and Opportunistic Infections in Feb 2023.",
Structural Biology Support,"Structural Biology, Computational Modeling and Structure Determination support for the mpox research community
CRSTAL-ID","Vaccine, Therapeutic",NIH/NIAID,Domestic,Ongoing,,2023 Q3,"Determination of high-resolution structures of mpox protein targets is critical as there are virtually no protein structures encoded from the MPOX genome other than computational models. The 2 CRSTAL-ID centers are currently prioritizing from a list of over a hundred targets from mpox Zaire 96-I-16. Ongoing structure determination efforts include work on Poxvirus Immune Evasion (PIE) proteins, the structure of F13L (target of Tecovirimat/ST-246) and DNA dependent RNA polymerase of poxviruses. The centers will also examine additional ligands and receptors, which can be structurally interrogated as complexes and inform the development of novel therapeutics.",
Structural biology studies in support of vaccine and molecular therapeutics development,X-ray crystallography studies at the Advanced Photon Source,"Vaccine, Therapeutic",DOE,Domestic,Ongoing,,,"Most protein structures deposited in the Protein Data Base (PDB) for monkey pox have come from Department of Energy light sources, including the Advanced Photon Source (Argonne), the Advanced Light Source (Lawrence Berkeley) and Stanford Synchrotron Radiation Light Source (SLAC).  In addition, the Advanced Photon Source (ANL) has three on-going studies with users: 1) Harvard Medical School, Dana-Farber Cancer Institute is conducting structural biology research related to how poxviruses evade the host anti-viral immune response and on an unpublished poxvirus protein structure; 2) Scripps Research Institute is working on mpox antigenic proteins; 3) Versiti Blood Research Institute, Medical College of Wisconsin is working mpox virus protein structures. This work will lead to the development of new vaccines and anti-viral drugs. 4) Yogesh Gupta, University of Texas Health Science Center at San Antonio is studying the structures and mechanisms of several proteins of mpox virus.",https://www.anl.gov/article/scientists-follow-the-world-health-organizations-gaze-toward-monkeypox-virus
Structural biology studies in support of vaccine and molecular therapeutics development,X-ray crystallography studies at the Stanford Synchrotron Radiation Lightsource (SSRL),"Vaccine, Therapeutic",DOE,Domestic,Ongoing,,,"Stanford Synchrotron Radiation Light Source at SLAC has a several on-going studies of Poxviridae.  The Division of Cell Biology, La Jolla Institute for Allergy and Immunology have studied the structural aspects of the vaccinia virus and its interaction with various antibodies. Live Vaccinia virus elicits antibodies to smallpox and mpox but does not replicate efficiently in humans. The virus is used to produce the two vaccines currently approved by the CDC for the prevention of mpox.  Crystals of proteins related to mpox virus are being prepared for structural studies to assess this issue.   Other SSRL users are beginning research programs with the goal of therapeutics developments to combat mpox and related poxviridae.  This work will lead to the development of new mpox vaccines and antiviral drugs.",
Drug Safety and Tolerability Study,Study to assess the safety and pharmacokinetics of TPOXX when administered orally for 28 days,Therapeutic,DoD/JPM CBRN Medical,USA,Ongoing,FY2023 Q2: Last Subject Last Visit,2023-12-31T00:00:00.000,"This study is a Phase 3, multicenter, double-blind randomized, placebo-controlled study to assess the safety, tolerability, and pharmacokinetics of oral TPOXX (600 mg) when administered orally for 28 days in adult subjects. A total of 445 - 460 subjects, ages 18 – 80, inclusive, will be enrolled and randomly assigned within stratified age groups (18-30 years, 31-45 years, and 65-80 years) to 1 of 2 treatment groups in an overall randomization of 4:1. Understanding that TPOXX can be administered safely for an extended period of time (28 days) in  adult subjects will help support the CDC EAP for orthopoxvirus treatment.",https://clinicaltrials.gov/ct2/show/NCT04971109
Monoclonal Antibody Discovery,Antibody Discovery for mpox,Therapeutic,NIH/NIAID,Domestic,Ongoing,,Ongoing,NIAID Vaccine Research Center is isolating monoclonal antibodies to be evaluated as therapeutics and diagnostic reagents. These studies will advance potential alternative mpox therapeutics and diagnostics.,
Therapeutic Efficacy Study,"STOMP (Study of Tecovirimat for Human Mpox Virus: A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Mpox Virus Disease",Therapeutic,NIH/NIAID,"Domestic
International: Peru 
Mexico
Brazil",Ongoing,"Initiated study in September 2022

2023 Q1: Open international sites

2023 Q4: Close to accrual

2023 Q4: Close to follow-up",2023 Q4,"This is a phase 3 double-blind, randomized controlled trial of TPOXX for the treatment of mpox in the outpatient setting in the United States and globally conducted through the AIDS Clinical Trials Group (ACTG).  The study includes an open-label cohort to ensure that certain high-risk populations (e.g., children, pregnant or breastfeeding people, those with severe disease, severe immune suppression, on potent inducing concomitant medications) are not randomized to placebo while also providing a means to collect important data on the safety and pharmacokinetics of TPOXX in this population. People with mpox infection, including people living with HIV, are eligible and encouraged to enroll. 530 volunteer participants will be randomly assigned to receive either tecovirimat or a placebo at a ratio of two to one. Investigators are evaluating if those taking tecovirimat heal more quickly than those taking placebo, among other data points.",https://actgnetwork.org/studies/a5418-study-of-tecovirimat-for-human-monkeypox-virus-stomp/
Therapeutic Efficacy Study,"PALM007: A randomized, placebo-controlled, double-blinded trial of the safety and efficacy of tecovirimat for the treatment of adult and pediatric patients with mpox virus disease in the Democratic Republic of the Congo",Therapeutic,NIH/NIAID,International: DRC,"Ongoing
Q4 2022: 1st site opened",2023 Q1: 2nd site to open,2025 Q3,"This is an in-patient double-bind, randomized, placebo-controlled trial in patients with Clade 1 mpox disease in the Democratic Republic of the Congo. This study will evaluate the clinical efficacy of tecovirimat compared to placebo, as assessed by time to lesion resolution, for patients with mpox disease. This study is supported by NIH/NIAID and the Institut National de Recherche Biomédicale of the Democratic Republic of the Congo (DRC).",
Therapeutic Monoclonal antibody Development,Therapeutic Monoclonal antibody Development,Therapeutic,NIH/NIAID,Domestic,Ongoing,2022 Q4: Study initiated,2023 Q4,"Study includes testing of approximately 6 monoclonal antibodies that broadly neutralize vaccinia virus (VACV), cowpox virus (CPXV), mpox virus (MPV), and variola virus (VARV) to identify optimal monoclonal antibodies combinations (2-3 per combination) that could be used as therapeutics and preventatives. Experiments also planning to include challenge studies in relevant animal models.",
Monoclonal Antibody (mAb) Development Efforts,Generative Unconstrained Intelligent Drug Engineering (GUIDE)/Accelerated Antibodies pan-orthopox prophylaxis,Therapeutic,DOD/JPEO,Domestic,Planning phases,"2023 Q2: GUIDE mAb candidates optimization

  
2023 Q2: mAb development start","2023 Q2: GUIDE mAb candidates optimization completion 

2025 Q1: mAb Phase 1 start","Through the DOD/CBDP/JPEO-CBRND Accelerated Antibodies program, will leverage DARPA Pandemic Prevention Platform (P3) antibody discovery efforts and GUIDE computational optimization of antibodies to further develop and manufacture a prophylactic pan-orthopox cocktail of antibodies. This effort will result in completion of phase 1 clinical trial and generation of cGMP material available to support phase 2 clinical trial and/or emergency use (minimum 5-10K doses).",
Therapeutic Development,"Novel Compound Screening, Lead Identification, Lead Optimization",Therapeutic,NIH/NIAID,Domestic,Ongoing,Screen Novel Compounds for activity against multiple pox viruses and profile active compounds for further development,2023 Q1- 2023 Q3,"USAMRIID and NIAID are collaborating to screen novel compounds for activity against smallpox, mpox, etc. and mechanism of action studies. The objective is to identify antiviral candidates with different mechanisms of action than tecovirimat which could then be used as a combined therapy, or in lieu of it. Further moving compounds in to lead optimization, safety, efficacy, and developmental process using newly developed mouse models and currently in-place NHP animal models.",
Diagnostic Development,"Development of rapid mpox diagnostic tests, including point-of-care and at-home use",Diagnostic,NIH/NIBIB,Domestic,Ongoing,2022 Q4: start EUA-enabling clinical studies,2023 Q1,"Efforts include working with the U.S. Department of Defense, industry, and academic partners to ensure two prototype point-of-care assays meet stringent FDA requirements for Emergency Use Authorization; and evaluation of tests via the Independent Test Assessment Program (ITAP) in partnership with the FDA. Rapid diagnosis of mpox at a healthcare provider’s location will limit spread by immediately starting treatment within minutes.",https://www.nibib.nih.gov/covid-19/radx-tech-program/ITAP
Diagnostics,Orthopox/Variola Virus Diagnostic on Next Generation Diagnostic System,Diagnostic,DOD/JPEO,Domestic,Planning phases,"Contract award by February 28, 2023",Pre-EUA for orthopox and variola by FY24 Q1,"This project is being rescoped due to the expiring Monkeypox Emergency Declaration.  The DOD/JPEO-CBRND will develop an orthopox/variola differential diagnostic test for use on the BioFire FilmArray 2.0 instrument to a level of pre-Emergency Use Authorization (pre-EUA).  The BioFire FilmArray 2.0 instrument is currently fielded to Role 2/3 Combat Care Providers (Army, Navy, Air Force). This effort will result in a test staged for preparedness at level that can be rapidly submitted for Emergency Use Authorization in response to future declared public emergencies for orthopox viruses or biowarfare incidents involving Variola.",
Diagnostic Assay Development,Diagnostic Assay Development,Diagnostic,DTRA JSTO/ USAMRIID,Domestic,Ongoing,"2022 Q3: Evaluate recombinant proteins/peptides. 

2022 Q4: Evaluate commercial constructs.",2023 Q3,Current project with USAMRIID is to develop recombinant proteins and peptides in support of development of a mpox immunoassay on the Magpix instrument. The goal of this project is to identify optimal protein targets for a mpox-specific immunological assay.,
Medical countermeasures,Testing of medical countermeasures within established MPXV animal models,Epidemiology,CDC,USA,Planned (normal long-standing program activity),Continuing Q1 2023,Ongoing,Ongoing studies to determine efficacy of new medical countermeasures (MCM) within characterized MPXV (or other OPXV surrogate) animal models. These studies are necessary to determine how effective an MCM will be at preventing or treating mpox disease within people. CDC has dedicated BSL-3 laboratories for mpox in vivo work. The program has a long-standing history performing these animal studies to progress orthopoxvirus MCM development.,
Diagnostic Assay Development,Diagnostic Assay Development,Diagnostic,DTRA/JSTO/ USAMRIID,Domestic,Completed,"MPXV-specific, real-time PCR assay",N/A,"USAMRIID developed a mpox virus-specific, real-time PCR assay validated to meet accreditation and regulatory compliance for a laboratory-developed test (LDT) available to DOD sites. The Defense Health Agency (DHA) announced the availability of this assay for clinical use effective June 27, 2022. USAMRIID is pursuing Emergency Use Authorization (EUA) for the assay. This assay provides an expedited, mpox-virus specific diagnostic result to Department of Defense laboratories and helps address patient concerns over lack of a definitive diagnosis when using the non-variola pan-orthopox assay.",
Enhanced Diagnostics/Detection,Development of an expeditionary sequencing and PCR assay development pipeline/diagnostic test,Diagnostic,"NMRC, NRL, DARPA, DTRA, JSTO",Domestic,Ongoing,"Oct 2022:  Software component - Obtain additional funding to move past successfully completed beta version;

Oct/Nov 2022: Follow-on successful proof on concept experiments with testing of viral, bacterial, and fungal pathogens and mixed sample types.","Software Development Completion:  May 2023; Estimated Project completion:  Late 2023

Diagnostic Test Validation Completed and Active","Project focused on developing an expeditionary on-demand PCR assay development pipeline and field sequencing for a variety of viral, bacterial, and fungal pathogens.  The goal is to establish a pipeline for use with any pathogen, which would have direct relevance to the rapid, on-demand development of mpox PCR assays and sequencing capabilities in field environments.

Naval Infectious Disease Diagnostic Laboratory (NIDDL) at NMRC is currently performing the CDC Non-variola Orthopoxvirus Real-time PCR Assay as part of the LRN. Results of this assay confirms identification of non-variola orthopoxvirus DNA, including mpox virus and is available to all DoD personnel.",
Laboratory Safety,Inactivation validation for Biological Select Agents and Toxins (BSAT) viral agents (to include poxviridae),Lab Safety,USAMRIID,Domestic,Ongoing,Validation of relevant clinical matrices to include poxviridae,2022 Q4,"USAMRIID is validating Trizol for multiple Biological Select Agents and Toxins (BSAT) agents to include members of the poxviridae family, including mpox. Validations are focused on Trizol LS to enable polymerase chain reaction (PCR) and next generation sequencing (NGS) assays outside of containment on inactivated samples. Validation inactivation protocols will ensure BSAT and non-BSAT inactivated poxviridae samples can be safely moved out of containment for further studies.",
Observational Study,"Observational studies to understand epidemiological characteristics, changing demographics over time, clinical course of illness, novel transmission routes, and transmission dynamics",Epidemiology,CDC,Domestic,Ongoing; case form data analyzed weekly; serosurveys in select communities underway,"2022 Q3: Complete sample collection 

2022 Q4: Results from serologies studies complete;

2023 Q1: Publish results of investigating cases reported in special populations; collecting data for in-depth exposure assessment among mpox cases with no reported male-male sexual contact in select health departments",2022 Q4,"CDC will investigate cases reported in special populations and with novel transmission routes by collecting and analyzing case report form data; investigate unusual cases (e.g., pediatrics, women, pregnant people); solicitation of electronic health care data resources to monitor health care utilization, and collection of additional exposure data in cases of mpox with no reported male-male sexual contact. These studies allow investigators to understand who is at risk for infection, how the virus is being transmitted, whether the outbreak is slowing or gaining momentum, and importantly, where interventions are likely to have the greatest impact in halting the spread of the virus. Case report form data are being analyzed weekly.",
Observational Study,Two retrospective seroprevalence surveys in the United States,Epidemiology,CDC,Domestic,"Ongoing laboratory work is complete, analysis ongoing",2023 Q2: Complete laboratory testing and publish results,2023 Q2,Investigate mpox virus infection occurring in the U.S. prior to earliest cases detected.  CDC will assess the prevalence of poxvirus antibodies retrospectively in serum collected during two different studies in select communities. The two studies are MWCCS (form Johns Hopkins University) and Doxy PEAP (from University of Washington). The testing of initial time points are completed. Testing for additional samples are ongoing.,
Serologic assay development,High-throughput serologic assay to distinguish between prior mpox infection and prior receipt of vaccinia-based vaccine,Epidemiology,NIH/NIAID,Domestic,Ongoing,,Ongoing,"NIAID scientists from the PREMISE initiative at the Vaccine Research Center (VRC) are developing a high throughput serologic assay that can distinguish between individuals who have been infected with mpox versus individuals who may have received a vaccinia-based vaccine, such as JYNNEOS or ACAM2000.  NIAID will use this approach in collaboration with national and international researchers, including the Centers for Disease Control and Prevention to conduct retrospective and prospective serological studies to better understand the extent of mpox virus circulation in the United States and worldwide.",https://www.niaid.nih.gov/research/premise
Virulence Potential Study,Evaluating the virulence of contemporary isolates with historical isolates,Epidemiology,NIH/NIAID,Domestic,Ongoing,"2023 Q1: Results published. Americo, J. L., et al. (2023). ""Virulence differences of mpox (monkeypox) virus clades I, IIa, and IIb.1 in a small animal model."" Proc Natl Acad Sci U S A 120(8): e2220415120.",2022 Q4,This study compares virulence of the 2022 mpox strains compared to historical West African isolates. This research will deepen knowledge of the virulence of different mpox virus clades and will investigate the genetic contributions to those differences.,
Transmission Study,Exploration of fomite and aerosol survival and spread,Epidemiology,NIH/NIAID,Domestic,Ongoing,2022 Q3: Results expected manuscript in progress,2022 Q3,"Efforts include survival of mpox virus on fomites and in aerosols, and establishment of small animal models to study transmission dynamics. Data from these studies will inform infection prevention and control efforts in the US and globally.",
Human-Animal Interface Study,"CDC diagnostic laboratory support for mpox in animals for state and local jurisdictions to test submitted animal samples, both domestic and wildlife, for mpox and monitoring suspected and confirmed animal cases",Epidemiology,CDC,Domestic,Ongoing,2023 Q1: Complete laboratory testing,Ongoing throughout the outbreak,"Animals, both domestic and wildlife, with clinical signs of mpox are sampled by state and local jurisdictions. CDC experts are available to support jurisdictions in collecting animal samples and conducting One Health investigations upon invitation. Animal samples are submitted to CDC for diagnostics. This line of study will support our understanding of the potential of mpox to spread zoonotically in the United States, a circumstance that could prolong the outbreak and diminish the likelihood of eradicating the infection.",
Human-Animal Environment Study,Assessing mpox infections in animals associated with human cases,Epidemiology,CDC,Domestic,Ongoing,"2023 Q1-Q2:
Complete study; publish results",Ongoing during the outbreak,"CDC is leading a One Health study to assess mpox infections in animals in households with human mpox cases.  Animals, including pets, with and without clinical signs are sampled from the homes of people isolating with mpox. Laboratory diagnostics for animal and environmental samples are conducted at CDC and results are provided to jurisdictions. One Health teams of local, state, and federal partners discuss next steps and recommendations to protect health. A questionnaire is administered to examine close contact between humans and animals, assess the environment and animal husbandry, and to assess risk factors for animal infections. This study will help identify susceptible animal species in the US and will help prevent the establishment of new animal reservoirs for mpox. 

This line of study will support our understanding of the potential of Mpox to spread zoonotically in the United States, a circumstance that could prolong the outbreak and diminish the likelihood of eradicating the infection.

Manuscript has been written and completed CDC clearance.  Will be submitted for publication in 23 Q2",
Human-Animal Environment Study,Ecological studies,Epidemiology,NIH/NIAID,International: Republic of Congo (RoC); Ghana,Ongoing,,,NIH has been conducting ecological studies in Africa to understand spillover events. Data from this study will inform efforts to prevent and control future spillover of mpox in Western and Central Africa.,
Serologic assay development and serosurvey,Developing high throughput serologic assays to understand magnitude of spillover in African sites,Epidemiology,NIH/NIAID,"International: Mali, Ghana, Republic of the Congo and Cambodia",Ongoing,"2022 Q4 team to Ghana
Manuscript published
Fischer RJ, Gallogly S, Evaluation of Five Buffers for Inactivation of Mpox Virus and Feasibility of Virus Detection Using the Panther Fusion® Open Access System. Viruses. 2022 Oct 10;14(10):2227. doi: 10.3390/v14102227. PMID: 36298782; PMCID: PMC9610623.",,"The assays under development will allow us to determine a history of mpox infection in people, and to distinguish between individuals who have been infected with a poxvirus and individuals who were vaccinated against smallpox. Will collaborate with Orasure on a rapid test. Data from this study will inform more accurate estimates of the prevalence of mpox spillover and transmission in Western and Central Africa, and will lead to the development of a diagnostic tool that could be used in future clinical studies of the immune response to mpox infection and vaccination.",
Clinical Specimen Study,Novel specimen validation,Epidemiology,CDC,Domestic,Complete. Manuscript has been published,"2023 Q1: Publish results for visit 1

2023 Q3: Publish results for subsequence visits",2023 Q1,"This is a study in collaboration with DC Health department to evaluate the presence of mpox DNA in throat, rectal, and blood specimens collected from individuals at risk for mpox but without lesions to inform potential use in diagnostic testing. This study will accelerate early, accurate detection of infection, and help to prevent ongoing transmission by potentially but expanding the range of specimen types that are approved for diagnostic purposes. The study has concluded, and results published.  Another manuscript is currently being drafted. .",https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciad145/7076896
Molecular Epidemiology Study,Genomic surveillance to monitor viral evolution and antiviral resistance,Epidemiology,CDC,Domestic,Ongoing,"2022 Q3: publish 100 US mpox virus genomes

2022 Q4: published article",Ongoing,"This study will monitor mpox virus lineages and mutations, especially tracking changes that could affect diagnostic testing or effectiveness of treatment (TPOXX). This study involves sequencing mpox virus from confirmed cases at CDC, monitoring mpox virus sequences produced by other groups found in public databases, and consulting with academic and state partners on mpox virus sequencing approaches, interpretations, and findings. If sequence changes are observed in the viral target of TPOXX, CDC will conduct laboratory testing to confirm the viral isolate remains sensitive to the therapeutic. This study will track genomic mutations that could signal changes in transmission or susceptibility to TPOXX, which would then impact mitigation efforts.",https://doi.org/10.1126/science.add4153
Serological Assay Development,Multiplex Serological Assay to Distinguish mpox from other orthopoxviruses (CREID Network Supported),Epidemiology,NIH/NIAID,Domestic and International,Ongoing,Preliminary specificity for mpox appears to be 85%,2023 Q2,"Scientists from the Centers for Research in Emerging Infectious Diseases (CREID) Network are developing multiplex serologic assays that can distinguish between mpox and other common orthopoxviruses for use with both animal and human specimens. Pending the results, the assay will be made available to the scientific community to facilitate seroprevalence studies in endemic regions.",
Observational Study,"Seroprevalence and Risk Factors of Mpox virus Infection Among Adults in Nigeria:  A Cross-sectional Exploration of the Implication for Mpox Epidemiology, Transmission, and Surveillance in Africa",Epidemiology,DHA/WRAIR,International: West Africa,Ongoing,"2023 Q1: Complete study documentation and
IRB submission and approval, validate MSD serology assay",2023 Q3,The prospective seroprevalence and risk factor mpox virus infection study aims to fill gaps in in resolving the key parameters of human vulnerability to emerging infectious diseases; from clinical diagnosis and molecular detection of mpox in humans to evaluating potential zoonotic reservoirs and transmission routes. Collected samples will serve as a starting point to better understand biomarkers of infections and transmission.,
Observational Study,Mpox disease burden and associated predictors in international at-risk populations,Epidemiology,DHA/WRAIR,"International: West Africa, Thailand, and Europe",Ongoing,"2023 Q1: Complete study documentation and
IRB submission and approval, validate MSD serology assay",2023 Q3,"This prospective and retrospective study will characterization of mpox infection, epidemiology, transmission, and clinical presentation in context of global outbreaks; leverage enhanced diagnostic approaches to inform knowledge products for prevention / risk mitigation strategies.",
Mpox serological assay development,Develop a mpox virus-specific serologic assay,Epidemiology,CDC,USA,Ongoing,Beginning Q4 2022,TBD,"Development of a mpox virus specific serology assay that can be universally used for both humans and animals will allow for the identification of infections following recovery from disease.  This will aid in the identification of animals that have been previously infected with mpox virus and provide data about which species may serve as hosts. Partner: CDC Division of Scientific Resources, USDA. The study is ongoing.",
Analysis of the VA Patient Population Affected by Mpox,Mpox in Veterans Affairs Healthcare System,Epidemiology,VA,Domestic,Planning,"1) Creating research team  

2) designing study – December 31, 2022",2023 Q1,"Description and comparison of unique populations affected by mpox:  1) test positive and treated 2) test positive and untreated 3) test negatives 4) test negatives and re-tested positively 3) indeterminant tests 4) inconclusive tests 5) presented for symptoms but untested. Outcomes include laboratory markers, genome wide sequencing, viral lineage/drug resistance/phylogenetics risk characteristics, clinical course, sequelae of illness. This study will provide information about test performance and illness course, but also help us understand characteristics of individuals presenting for testing to inform testing strategies, including timing for retesting and the value of testing with exposure but without symptoms. An abstract was submitted for presentation at the Council of State and Territorial Epidemiologists 2023 Annual Conference, titled “Epidemiology of the Mpox Outbreak in the Veterans Health Administration (VHA), 2022”.",
Biorepository System,Veterans Affairs Science and Health Initiative to Combat Infectious and Emerging Life-Threatening Diseases (VA SHIELD),Epidemiology,VA/VHA,Domestic,Initiated,"Specimens collected; Specimens used for research – December 31, 2022",Ongoing part of VA’s research pandemic preparedness actions,"VA SHIELD collects de-identified biological samples from U.S. Veterans affected by emerging life-threatening health conditions. Associated clinical and demographic information is maintained in a data repository, to help correlate samples and experimental findings with patient demographics, clinical experience and management, vaccinations, and comorbidities. Specimens are available to investigators within and outside VA via an efficient, secure, vetted distribution system. The number of collected specimens now totals over 40,000 (most of the specimens are COVID positive NP swabs, MPX swabs, plasma, and serum).",https://www.research.va.gov/programs/shield/about.cfm
Monitoring International Mpox Infections,No formal research protocol – monitoring the epidemic among people living with HIV/AIDS to determine whether additional support is needed,Epidemiology,DOS/S/GAC,"International: Countries with PEPFAR programs (Angola, Benin, Botswana, Brazil, Burkina Faso, Burma, Burundi, Cambodia, Cameroon, Cote d’Ivoire, Dominican Republic, DRC, El Salvador, Eswatini, Ethiopia, Ghana, Guatemala, Guyana, Haiti, Honduras, India, Indonesia, Jamaica, Kenya, Kyrgyz Republic, Kazakhstan, Laos, Lesotho, Liberia, Malawi, Mali, Mozambique, Namibia, Nepal, Nicaragua, Nigeria, Panama, Papua New Guinea, Philippines, Rwanda, Senegal, Sierra Leone, South Africa, South Sudan, Tajikistan, Tanzania, Thailand, Togo, Trinidad and Tobago, Uganda, Ukraine, Vietnam, Zambia, Zimbabwe)",Ongoing,None,TBD,"Through communication with U.S. Government in-country staff, the office of the Global AIDS Coordinator is monitoring the impact of the mpox virus outbreak in endemic and non-endemic countries on President’s Emergency Plan for AIDS Relief (PEPFAR) beneficiaries and programs.","https://www.state.gov/statement-from-u-s-global-aids-coordinator-ambassador-dr-john-nkengasong-on-use-of-the-pepfar-platform-for-monkeypox-response/#:~:text=As%20part%20of%20the%20U.S.,prevent%20and%20respond%20to%20monkeypox."
Computational studies of phylogeny and predicting structures of all the monkey pox proteins,Computational studies of monkey pox protein and emerging variants,Epidemiology,DOE/NIAID,Domestic,Ongoing,,,"Argonne (in a collaboration with University of Chicago, University of Virginia and J. Craig Venter Institute) is conducting mpox studies for an NIAID-supported center Bioinformatics Resource Center [BV-BRC https://www.bv-brc.org] that includes studies of phylogeny, predicting structures of all the mpox proteins (~180) and assessing the proteins on a therapeutics pipeline.  They are also tracking all the new variants and providing summary reports to NIAID leadership.",
Mpox Virus detection,Sequencing monkey pox virus from Chicago area wastewater,Epidemiology,DOE,Domestic,Feasibility studies completed,,,Scientists at Argonne are sequencing mpox from wastewater samples collected in the Chicago area to assess whether sequencing will be more consistent and more sensitive than some of the current qPCR/dPCR methods that have produced mixed results.,
Evolution of Mpox,Assessment of human enzyme cAPOBEC3 impacts on driving mpox evolution,Epidemiology,DOE,Domestic,Ongoing,,,"Scientists at Los Alamos recognized a very unusual pattern of mutation that is operative in HIV-1 evolution that is driving mpox evolution in the outbreak (and during its initial spread in 2017). The mutations in the outbreak viruses are driven by human enzyme cAPOBEC3, which is part of the innate immune system.  Other unusual mutation patterns are being defined, along with strategies for dealing with these issues for multiple alignments and studying mpox’s emergence in Nigeria. Computational modeling is being used to study the dynamics of distinctive variants to track evidence for evolutionary selection and to understand if the variants have implications for epidemic forecasting.  This work will enable a better understanding of mpox virus evolution.",
Virus genome sequencing,Challenges in sequencing and assembling mpox viral genome,Epidemiology,DOE,Domestic,Ongoing,,,"Scientists at Los Alamos are advising the CDC genomics group on how to best overcome some of the sequencing and assembly challenges that this large viral genome has compared with SARS-CoV-2. “Multiple lineages of monkeypox virus detected in the United States, 2021-2022.”, joint with CDC, Science. 2022 Nov 4;378(6619):560-565. doi: 10.1126/science.add4153. Epub 2022 Oct 20. PMID: 36264825.",
Molecular Therapeutics,Computational design of potential pan-orthopox anti-viral,Therapeutics,DOE,Domestic,Planned,,,Lawrence Livermore is conducting studies as part of the DoD/JPEO Generative Unconstrained Intelligent Drug Engineering (GUIDE) program to establish the feasibility of undertaking a computational design campaign to develop a pan-orthopoxvirus therapeutic/prophylactic antibody.,
Animal reservoirs,Investigation of animal reservoirs,Epidemiology,CDC,"Cameroon, Nigeria",Ongoing,"2023 Q3,4: Laboratory analysis of specimens",2023 Q3,"This study assesses the prevalence of antibody-positive blood samples collected from animals in forest areas where cases of mpox have been reported. Activities include collecting tissue and swab samples from small mammals and testing for presence of mpox virus in high-risk areas. These activities will further our understanding of natural transmission patterns and sources of mpox virus, aiding our ability to stem future introductions into the United States and to assist endemic countries in minimizing the impact of the disease in their countries.",
Passive zoonotic disease surveillance,Ongoing Passive Surveillance of Sick or Dead Wildlife Species,Epidemiology,FWS)/NWRS,USA,Ongoing,N/A,N/A,"There is ongoing passive surveillance for sick and dead wildlife species on national wildlife refuges for various zoonotic disease agents (e.g., highly pathogenic avian influenza (HPAI), tularemia, anthrax, plague, rabies, etc.). The FWS Wildlife Health office within the NWRS receive notifications about sick or dead wildlife from FWS refuge personnel. FWS refuge staff may also be in communication with local and/or state public health agencies, state public health veterinarians, etc., along with the FWS Wildlife Health office. The Wildlife Health office staff discuss pertinent biosafety and biosecurity measures to implement based on the specific report and proper sample collection and shipping procedures if samples will be sent to a veterinary diagnostic laboratory, the National Wildlife Health Center, or another appropriate laboratory depending on the sample(s) submitted for diagnostic testing. There is no current active disease surveillance in place for mpox virus in wildlife on the national wildlife refuges.",
Human-animal interface study,Investigation of zoonotic risk factors among mpox cases in Nigeria,Epidemiology,CDC,Nigeria,Planned (normal long-standing program activity),FY23,"September 30, 2023 (with option to extend 1 year)","This project will use mixed methods (qualitative and quantitative) interviews to examine mpox risk factors at the human-animal interface for human mpox cases. This will provide missing data about how people in Nigeria are being exposed to infected animals. Partners: Penn State, Nigeria Centre for Disease Control, National Veterinary Research Institute",
Mpox virus ecology study,Assessing the ecological aspects of mpox virus in Nigeria: building capacity for field and lab-based investigations,Epidemiology,CDC,Nigeria,Ongoing (normal long-standing program activity),,TBD,"A One Health Team has been trained to capture, sample, and test animals for mpox virus infections. The team continues to collect animal samples for lab analysis. Study will provide information about which types of animals are naturally infected with mpox virus in the environment. Partners include: Nigeria Centre for Disease Control, National Veterinary Research Institute, Federal Ministry of Agriculture and Rural Development, African Field Epidemiology Network.",
Human-animal interface/value chain risk study,Examining the human-animal interface: assessing mpox risk along the wild game meat value chain,Epidemiology,CDC,Democratic Republic of the Congo,Ongoing (normal long-standing program activity),2nd field session Q1 2023,TBD,"Examining the human-animal interface in rural DRC where people regularly hunt and consume small mammals as an essential protein source. This project will generate quantifiable data on characteristics of hunters, analysis of hunting effort, small mammal species captured, and the disposition of those animals.  These data will be analyzed spatially and examined for risk factors for primary zoonotic transmission of mpox virus and other zoonotic pathogens into human populations. Study will provide information about how human behaviors may increase the risk of mpox virus transmission from animals to humans. Partners include: University of Kinshasa, Kinshasa School of Public Health.",
Ecology of suspected reservoirs,Studies to examine the ecology of suspected mpox reservoirs,Epidemiology,CDC,Democratic Republic of the Congo,Ongoing (normal long-standing program activity),Field session Q1 2023,TBD,"The current study uses camera traps to assess the activity patterns and relative abundance of suspected mpox reservoirs in disturbed and undisturbed environments to examine potential mpox risk at the human-animal interface in these habitats. This will provide information on how animal behaviors may increase the risk of mpox virus transmission from animals to humans. Partners include: University of Kinshasa, Kinshasa School of Public Health.",
Mpox virus  ecology study,Investigating potential small mammal reservoirs in Sierra Leone,Epidemiology,CDC,Sierra Leone,Ongoing (normal long-standing program activity),,TBD,"A team at the University of Njala has been trained to capture, sample, and test animals for mpox virus infections. The team continues to collect animal samples for lab analysis. Study will provide information about which animals are naturally infected with mpox virus in the environment. Partner: University of Njala.",
Mpox virus  ecology study and outbreak response,Assessing mpox virus prevalence in small mammals and outbreak response,Epidemiology,CDC,Cameroon,Ongoing,,2024,"A Team from the University of Douala has been trained to capture, sample, and test animals for mpox virus infections. The team continues to collect animal samples for lab analysis during outbreak response efforts. This will provide information about which animals may be transmitting mpox virus to humans. Defense Threat Reduction Agency (DTRA) funded, Partners include: Ministry of Public Health, Centre Pasteur in Cameroon, University of Doula, National Veterinary Laboratory",
"Mpox virus ecology studies, capacity building, viral sequencies, modeling, human surveillance",Mpox Threat Reduction Network (TRN): Decreasing the threat of mpox emergence and spread in West and Central Africa,Epidemiology,DTRA/CDC,"International: Nigeria, Cameroon, Democratic Republic of the Congo, Gabon",Ongoing,,2028,"This study is a wide-ranging project to reduce mpox cases in endemic countries.  A large part of the project will assess potential animal reservoirs and examine the ecological aspects of mpox virus though research and capacity building. The project will provide information about animals involved in the transmission of mpox virus to humans, but also about how human and animal behaviors may increase the risk of mpox virus transmission from animals to humans. Defense Threat Reduction Agency (DTRA) funded. Partners include: Nigeria Centre for Disease Control (NCDC), National Veterinary Research Institute in Nigeria (NVRI), African Field Epidemiology Network (AFENET), Centre Pasteur in Cameroon (CPC), University of Doula (UDLA), National Veterinary Laboratory (LANAVET), National Biomedical Research Institute in Kinshasa (INRB), International Center of Medical Research of Franceville, Gabon (CIRMF).",
Susceptibility study,"Investigating the susceptibility of white-footed mice (Peromyscus leucopus), rats (rattus rattus), and prairie dogs to 2022 mpox virus infection",Epidemiology,CDC,USA,Ongoing (new activity by program as result of current outbreak),"Q2 2023: The Peromyscus study has been completed and sample processing and laboratory testing has begun.

2023 Q3: Rattus rattus and prairie dog studies will begin",2024,This study examines the pathogenesis of multiple mpox virus strains in domestic wild animals and will yield data about whether or not these rodents could become a potential mpox virus host in North America.,
Viral persistence,Identify persistence of mpox virus in bodily fluids,Epidemiology,CDC,USA (Puerto Rico and New York City),Q1 2023 Will start enrollment late March 2023,Just started,Q4 2023 (1 year project),"These projects investigate viral persistence in semen and other body fluids. Project data on the effect of mpox virus on sperm count, concentration, motility, or morphology post-infection could enable informed decisions about reproductive health.  The project in partnership with Puerto Rico and Columbia University involves multiple sites using a common approach and protocol. 

The  study will involve collection of serial specimens from confirmed and probable male mpox cases post-diagnosis to: 1) Determine the presence, persistence, or recurrence of mpox virus in seminal fluid, saliva, conjunctival fluid, oropharyngeal swabs, and rectal swabs, and whether it is replication competent, 2) Describe orthopoxvirus antibody response in blood, 3) Characterize changes in sperm count, motility, or quality in the convalescent phase, and 4) Characterize psychosocial, behavioral and clinical sequelae from mpox illness over time.",
Transmission Dynamics and Modes,"Ecological and Epidemiological Investigations of High-Consequence Zoonotic Pathogens at the Livestock, Wildlife and Human Interface",Epidemiology,USDA Agricultural Research Service,TBD,Planned,2022 Q4: Initiate study,TBD,"Domestic and wild animals will be monitored for evidence of mpox infection to better understand whether animals play a role in harboring, transmitting, or persistence of the virus. In collaboration with Institut National de Recherche Biomédicale (INRB), and the Institute of Tropical Medicine Antwerp (ITM) we will explore evidence of spillover in the Democratic Republic of Congo and in border areas with Angola and Uganda. These groups have established study locations in areas where mpox cases are frequently observed.  In addition, we will partner with UCLA and NIH Rocky Mountain Laboratories for analysis of samples collected in the Republic of Congo including border areas. Samples will be assessed for evidence of antibodies to orthopox virus as well as the presence of viral DNA as well as live virus if lesions are present in any collected animals.",
Transmission Dynamics and Modes,Evaluation of susceptibility of select animal species.,Epidemiology,USDA Agricultural Research Service,TBD,Planned,2022 Q4: Initiate study,TBD,"As the mpox virus continues to spread, there is the potential for the virus to become established in animal populations through contact with infected humans or environments, so the susceptibility of various animal species to infection will be assessed.  Determine the potential risk of transmission of mpox virus to animals including domestic (agricultural, companion), peri-domestic animals (e.g. rodents), and wildlife.",
Serosurveys and Improved Serological Surveys,Development of a mpoxspecific immunoassay,Epidemiology,USDA Agricultural Research Service,TBD,Planned,2022 Q4: Initiate study,TBD,"Testing methods to distinguish whether an animal or person has been exposed to Mpox or another virus in the same virus family will be developed. Identify specific peptides / protein fragments (encoded or absent in MPXV genome) that would allow differentiation of mpox infection from vaccination and previous smallpox or other orthopox virus infection. Currently available assays are only able to distinguish if a person / animal has been exposed to an orthopox infection. Assays cannot distinguish if the response was the result of a mpox infection or another orthopox virus infection. 

If specific peptides/protein fragments are identified, USDA and Columbia University will partner with CDC to develop a mpox specific assay.",
Biosurveillance study,Mpox Threat Reduction Network (MPX-TRN): Using the Sentinel Sites in the DRC as a regional training center to create sustainable biosurveillance systems in DTRA Priority Countries,Epidemiology,DTRA-CTR/BTRP,"International: Democratic Republic of Congo, Uganda, Cameroon",Ongoing,Initiate sample testing and MPV genome sequencing; Establish training center,Base period ends: 2024 Q3,"This study aims to determine the incidence, distribution, and transmission chain of mpox virus in the region and strengthen capacities for case detection, biosurveillance, and laboratory diagnostics in order to create a sustainable biosurveillance system.",
Education and Training,Sample Collection Training and Capacity Building,Education,WRAIR,International: West Africa,Closing out both training iterations,"2022 Q4: Manuscript, documenting the training approach and associated outcomes, journal submission is on-going",2023 Q3,"WRAIR, through the Joint West African Research Group, facilitated training for personnel to identify potential infected patients and collect mpox samples for diagnostic testing. This builds capacity for early identification of mpox in areas with endemic disease and/or reservoirs, where spillover to humans is most likely to occur.",
International Training and equipment upgrades/maintenance,Enhancing Biosafety and Biosecurity of High Containment Facilities at the Institut National de Recherche Biomédicale (INRB),Education,DOS/ISN,International: DRC,Ongoing,In-person workshop in October 2022,2022 Q4,"Through a series of virtual biosafety and biosecurity trainings participants will be trained on biorisk management and will develop an institutional biosafety and biosecurity program plan. This effort will build institutionalized capacity at the INRB to ensure that equipment in laboratories working with and storing high-consequence pathogens, such as mpox virus, is operating optimally and with all necessary biosafety and biosecurity considerations.",
Computational and Bioinformatics support; Outreach and Communication Activities,Computational and bioinformatics support for the mpox virus research community (BV-BRC),Outreach,NIH/NIAID/NLM,Domestic and International,Ongoing,,"2023 Q1
and ongoing","The BV-BRC provided and extended public access to computational platforms and analysis tools to accelerate large-scale data analysis capabilities needed to monitor and assess countermeasures against monkeypox virus. During 2022 updated mpox genome annotations and orthopoxvirus analytic tools were extended in collaboration with experts of the International Committee on Taxonomy of Viruses (ICTV).  In collaboration with the BRCs, NIH/NLM, orthopoxvirus stakeholders, and the University of California Santa Cruz (UCSC) the UCSC Genome Browser mpox virus reference genome browser was launched. Furthermore, the BV-BRC hosted the Mpox and Orthopoxvirus Mini-Symposium on bioinformatics resources, tools, and research for the research community, bringing together nearly 800 registrants with 478 attendees from over 40 countries.",https://www.bv-brc.org/
